Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl- 2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. Belongs to the nuclear hormone receptor family. NR1 subfamily. Note: This description may include information from UniProtKB.
Protein type: Nuclear receptor; DNA-binding
Cellular Component: nucleus
Molecular Function: protein domain specific binding; ligand-dependent nuclear receptor activity; NFAT protein binding; zinc ion binding; metal ion binding; receptor activity; drug binding; phosphatase binding; protein binding; DNA binding; ubiquitin conjugating enzyme binding; protein heterodimerization activity; sequence-specific DNA binding; protein complex binding; steroid hormone receptor activity; transcription factor activity; lipid binding
Biological Process: transcription from RNA polymerase II promoter; epidermis development; intracellular receptor-mediated signaling pathway; wound healing; transcription, DNA-dependent; positive regulation of transcription, DNA-dependent; rhythmic process; behavioral response to nicotine; glucose metabolic process; lipoprotein metabolic process; negative regulation of transcription from RNA polymerase II promoter; fatty acid metabolic process; regulation of circadian rhythm; negative regulation of appetite; response to insulin stimulus; positive regulation of gluconeogenesis; regulation of transcription, DNA-dependent; regulation of gene expression; regulation of fatty acid metabolic process; positive regulation of fatty acid oxidation; response to hypoxia; steroid hormone mediated signaling; positive regulation of transcription from RNA polymerase II promoter; circadian regulation of gene expression; lipid metabolic process; negative regulation of blood pressure; negative regulation of protein binding
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.